Tag Archive for: Pharma

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

/in

New therapies will allow patients greater choice and flexibility in the control of CNS disorders Barcelona, Spain / Düsseldorf, Germany and Athens, Greece – 12 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in […]

Read more

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

/in

Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025. Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous […]

Read more

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)

/in

London, UK, Barcelona, Spain and Düsseldorf, Germany – 5 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for Health and Care Excellence (NICE) in the UK has issued a positive recommendation for the use of ublituximab (150 mg concentrate […]

Read more

Neuraxpharm reports another year of sustained growth and international expansion

/in

CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus on innovation Barcelona, Spain and Düsseldorf, Germany – 14 November 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its rebranding as Neuraxpharm […]

Read more

Optimum’s hot topic: How do you turn a 10-person biotech into a $1.1 billion company sale in the space of seven years?

/in

During the BIO-Europe conference in Stockholm, Optimum co-hosted a special reception featuring a fireside chat with Renée Aguiar-Lucander, former CEO of Calliditas, who led the Swedish company since 2017 until recently – taking it from small biotech to its $1.1 billion acquisition. Here, we tell the story of her remarkable seven-year journey with the firm.  […]

Read more